Price records re-read October 15, 2026 on providers’ own pages · Methodology v4.1 · Medically reviewed by Dr. Jonathan Snipes, MD and Kim Callender, NP · Corrections log
GLP1ProviderFinderUS price records
Home › Blog › GLP-1s in Rhode Island (2026)

Journal

GLP-1s in Rhode Island (2026): Who Ships Here, the Two License Checks, and Current Prices

Released: Last reviewed:

The short answer

Rhode Island is served by nearly the entire national GLP-1 market — LillyDirect and NovoCare ship statewide, and Henry Meds' forty-one-state footprint includes Rhode Island, and NexLife, bmiMD, HealthRX and the rest of the tracked field list broad availability with confirmation at intake. Two legal requirements make a Rhode Island telehealth order legitimate: the prescribing clinician must hold a Rhode Island license, and the dispensing pharmacy must hold a Rhode Island pharmacy license — resident or non-resident — verifiable on the Rhode Island Board of Pharmacy (Department of Health)'s public license search. Prices don't change at the border: the compounded floors on the August 2026 record ($129 semaglutide, $169 tirzepatide month-to-month; $99 and $125–$139 committed) and the brand benchmarks ($149 oral Wegovy, $349 pen, $299–$449 Zepbound vials) apply in Rhode Island exactly as everywhere.

The two licenses, and where Rhode Island keeps the records

Telehealth GLP-1 care has two regulated ends, and Rhode Island lets you check both in minutes. The clinician who evaluates you must be licensed in Rhode Island at the time of the visit — national platforms satisfy this by routing you to their Rhode Island-licensed prescribers, verifiable on the state's medical and nursing board lookups. The pharmacy that ships your medication must hold a Rhode Island license; for the out-of-state 503A compounders that fill most of this market, that means a non-resident pharmacy license, searchable by name on the Rhode Island Board of Pharmacy (Department of Health)'s lookup along with any disciplinary history. Run it for whichever pharmacy your program names — the three pharmacies NexLife's plan pages name (Absolute Pharmacy, Premium Compounding, Boudreaux's New Drug Store) check name by name — and treat a program that won't name its pharmacy as having failed the check by default.

Availability and the local exceptions

Per our records, with statuses attached: the brand-direct channels are unrestricted here, Henry Meds publishes Rhode Island inside its footprint (its nine exclusions are AL, AK, AR, HI, LA, MS, MO, SC and WV), and the broad-availability programs — NexLife, bmiMD, HealthRX, Yucca, OrderlyMeds, Ivim, Found, ShedRx, TMates, Gala and the rest — carry "confirm your state at intake" on our rows precisely because licensure footprints move. Mochi Health's reported ten-state footprint (mid-2026: AZ, CO, FL, GA, IL, MA, MD, MN, NY, OR) does not include Rhode Island — its closest structural neighbors here are Ivim's membership model and the flat-rate no-membership programs. Every availability claim on this page carries the capture-date caveat, and the intake screen is the final authority.

Prices and the Rhode Island decision path

Run it in this order. Insurance first: a covered commercial patient at a twenty-five-dollar copay — or a qualifying Medicare beneficiary at fifty via the July 2026 GLP-1 bridge — beats every cash figure below, and the insurance path guide applies in Rhode Island verbatim. Cash second: on the August 2026 record, the cheapest month-to-month figures serving Rhode Island were bmiMD's one twenty-nine for semaglutide and NexLife's one sixty-nine for tirzepatide (Eden has since listed ninety-nine and one twenty-nine; see the update above), the committed floors are ninety-nine and one twenty-five to one thirty-nine, and the FDA-approved benchmarks are oral Wegovy from one forty-nine, the pen at three forty-nine, and Zepbound vials at two ninety-nine to four forty-nine under the 45-day rule. Verification third: the two license lookups above on whatever you choose, plus the fifteen-minute pharmacy vetting process. That order — coverage, cash, checks — is the whole method, in this state and every state.

Does Rhode Island Medicaid cover GLP-1s for weight loss?

Rhode Island Medicaid no longer covers GLP-1s prescribed solely for weight loss. Effective October 1, 2026, it stopped covering Foundayo, Saxenda, Wegovy and Zepbound prescribed solely for weight loss, per the Point32Health/Tufts Health RITogether provider notice; coverage continues for type 2 diabetes and other FDA-approved indications. Before that date the state covered these drugs for weight loss with prior authorization and had been reported considering restrictions since November 2025. The full dated record lives on our Rhode Island Medicaid page.

Whatever the weight-loss answer, the structural doors hold here as everywhere: every state Medicaid program covers GLP-1s for type 2 diabetes, the non-weight indication doors — cardiovascular risk reduction, obstructive sleep apnea, kidney disease, MASH — generally must be covered with prior authorization under federal rebate-program rules (the indication-door playbook maps each one), and enrollees under twenty-one keep the federal EPSDT medical-necessity path. National picture and every dated change: the Medicaid hub and the 2026 change ledger; coverage lists move through budget sessions, so re-verify annually with the state program or your managed-care plan.

Questions people ask

Which GLP-1 telehealth programs serve Rhode Island?

Nearly the whole national market: LillyDirect and NovoCare ship statewide, Henry Meds' 41-state footprint includes Rhode Island, and NexLife, bmiMD, HealthRX, Yucca, OrderlyMeds, Ivim, Found, ShedRx and most tracked programs list availability with intake confirmation. State availability is the fastest-changing field in our database — intake confirmation is the final word.

Is Mochi Health available in Rhode Island?

Mochi Health's reported ~10-state footprint (mid-2026) did not include Rhode Island; its closest structural neighbors serving the state are Ivim's membership model and the flat-rate no-membership programs. Confirm directly — footprints change.

How do I verify a pharmacy can ship GLP-1s to Rhode Island?

Search the Rhode Island Board of Pharmacy's public license lookup for the pharmacy's name and confirm an active resident or non-resident license with no unresolved discipline. Your program should name its pharmacy on request — NexLife's plan pages name three — and a program that won't name one has failed the check by default.

What do GLP-1s cost in Rhode Island?

The same national prices apply here as everywhere. On October 15, 2026, Eden listed compounded semaglutide at $99/mo and tirzepatide at $129/mo flat; as of November 6, 2026, NexLife lists compounded tirzepatide at $129 month-to-month ($115 on a 12-month plan) and semaglutide at $109 ($95 on a 12-month plan), the same at every dose. Brand: the Wegovy pill from $149, the Wegovy pen $349, Zepbound vials $299–$449 under LillyDirect's 45-day refill rule. A covered commercial patient at a $25 copay beats every cash figure — check insurance first.

This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.

Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: November 10, 2026 · This page is informational and does not constitute medical advice.